Santen Pharmaceutical Co., Ltd.
JPX: 4536.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Takeshi Ito
- Employees
- 3,744
- Headquarters
- Osaka, Japan
- IPO year
- 2001
- Market cap
- ¥520.3B
- Website
- https://www.santen.com
Loading 4536…
Loading profile data…Frequently asked questions about 4536
What does Santen Pharmaceutical Co., Ltd. (4536.T) do?
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial...
Where does 4536.T trade?
Santen Pharmaceutical Co., Ltd. (4536.T) trades on the Tokyo Stock Exchange.
What sector is 4536.T in?
Santen Pharmaceutical Co., Ltd. (4536.T) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Santen Pharmaceutical Co., Ltd.?
Takeshi Ito is the chief executive officer of Santen Pharmaceutical Co., Ltd. (4536.T).
Where is Santen Pharmaceutical Co., Ltd. headquartered?
Santen Pharmaceutical Co., Ltd. is headquartered in Japan.
Does 4536.T pay a dividend?
Yes — Santen Pharmaceutical Co., Ltd. (4536.T) paid a trailing twelve-month dividend of JPY 38.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 4536.T go public?
Santen Pharmaceutical Co., Ltd. (4536.T) completed its initial public offering in 2001.